<SEC-DOCUMENT>0001193125-24-174612.txt : 20240703
<SEC-HEADER>0001193125-24-174612.hdr.sgml : 20240703
<ACCEPTANCE-DATETIME>20240703060255
ACCESSION NUMBER:		0001193125-24-174612
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240703
FILED AS OF DATE:		20240703
DATE AS OF CHANGE:		20240703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241098164

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d845350d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as July 3, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d845350dex991.htm">Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July 3, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d845350dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g845350dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g845350dsp4a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss
Clinical Results </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; July 3rd, 2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a
clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces details for an upcoming oral presentation at the European Society for Medical
Oncology (ESMO) Virtual Plenary session on July&nbsp;11, 2024, featuring new clinical data in patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (Cohort B) in the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(KEYNOTE-PNC-34)</FONT></FONT> Phase IIb trial, and a webcast to discuss these clinical results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ESMO Virtual Plenaries are monthly presentations of the latest, original scientific data, including <I>&#147;Phase II trials which</I> <I>demonstrate
remarkable therapeutic benefit, scientific insight or progress in an area of unmet need&#148;.</I> The oral presentation will announce the substantially improved overall response rate, as advised 27&nbsp;June 2024, and additional data in patients
with first line head and neck squamous cell carcinoma who have negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> (Cohort B). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Details for the ESMO
Plenary presentation </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Title:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Eftilagimod Alpha (Soluble <FONT STYLE="white-space:nowrap">LAG-3)</FONT> &amp; Pembrolizumab in First-Line Recurrent or Metastatic Head&nbsp;&amp; Neck Squamous Cell Carcinoma: Primary Results from Cohort B (CPS &lt;1) of the <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> Study</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Presenter:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dr.&nbsp;Robert Metcalf, The Christie NHS Foundation Trust, Manchester, U.K.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Format:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Oral Presentation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date/Time:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">18:30-19:30</FONT> Central European Time (CEST), July&nbsp;11, 2024</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Webcast Details </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep
will host a webcast to discuss the clinical data. A replay of the webcast will be available under the Events section of Immutep&#146;s website after the event. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date/Time:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Friday, July&nbsp;12, at 9am AEST (7pm ET July 11)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Register:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Link to register for webcast</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Questions:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investors are invited to submit questions in advance via <U>immutep@morrowsodali.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">TACTI-003</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(KEYNOTE-PNC-34)</FONT></FONT> trial is
an ongoing Phase IIb study evaluating eftilagimod alfa (efti), Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist, in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc.,
Rahway, NJ, USA) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first line treatment of recurrent or metastatic
head and neck squamous cell carcinoma (HNSCC). The randomized Cohort A portion of the study is evaluating efti in combination with pembrolizumab as compared to pembrolizumab monotherapy in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT>
positive (Combined Positive Score [CPS] &#8805;1) tumours, whereas Cohort B is evaluating efti in combination with pembrolizumab in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative tumours. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g845350dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g845350dsp4a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of the study is Overall Response Rate of evaluable patients according to RECIST 1.1. Secondary
endpoints include Overall Survival, Overall Response Rate according to iRECIST, Progression Free Survival, and Duration of Response. For more information about the Phase IIb trial, visit clinicaltrials.gov (NCT04811027). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alfa (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells,
CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-</FONT><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that
further boost the immune system&#146;s ability to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug
Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte
Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to
leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
c.strong@morrowsodali.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta,
VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g845350dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g845350dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( $H TP,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MI,VKZG+(0/-U&UO[58KED10B.8[VXCPH4!2% PH Y\IJSEB:W-)R]I'FE?\
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M:'A?PO;6^J!&1=6OIKK5-3B1AM=;>ZU":4V@9<AO($6X$ALBC8-CUGI^'Z4
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? * "@ H * "@ H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g845350dsp4a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g845350dsp4a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M?&G_ ).__&*/K6._Y^U?Q_R#^U,^_P"@O%_=/_Y$/^%B?%__ *&7QI_Y._\
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M *"\7]T__D0_X6)\7_\ H9?&G_D[_P#&*/K6._Y^U?Q_R#^U,^_Z"\7]T_\
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MR#^U,^_Z"\7]T_\ Y$/^%B?%_P#Z&7QI_P"3O_QBCZUCO^?M7\?\@_M3/O\
MH+Q?W3_^1#_A8GQ?_P"AE\:?^3O_ ,8H^M8[_G[5_'_(/[4S[_H+Q?W3_P#D
M0_X6)\7_ /H9?&G_ ).__&*/K6._Y^U?Q_R#^U,^_P"@O%_=/_Y$/^%B?%__
M *&7QI_Y._\ QBCZUCO^?M7\?\@_M3/O^@O%_=/_ .1#_A8GQ?\ ^AE\:?\
MD[_\8H^M8[_G[5_'_(/[4S[_ *"\7]T__D0_X6)\7_\ H9?&G_D[_P#&*/K6
M._Y^U?Q_R#^U,^_Z"\7]T_\ Y$/^%B?%_P#Z&7QI_P"3O_QBCZUCO^?M7\?\
M@_M3/O\ H+Q?W3_^1#_A8GQ?_P"AE\:?^3O_ ,8H^M8[_G[5_'_(/[4S[_H+
MQ?W3_P#D0_X6)\7_ /H9?&G_ ).__&*/K6._Y^U?Q_R#^U,^_P"@O%_=/_Y$
M/^%B?%__ *&7QI_Y._\ QBCZUCO^?M7\?\@_M3/O^@O%_=/_ .1#_A8GQ?\
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M_A8GQ?\ ^AE\:?\ D[_\8H^M8[_G[5_'_(/[4S[_ *"\7]T__D0_X6)\7_\
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M_P B?9VD_P#(*TS_ +!]E_Z31U]:?L1Z7X,_Y%^#_L(:]_Z?M3H ZF@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \+TG_D%:9_V
*#[+_ -)HZ /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
